Power Morcellator Lawsuit News: Massachusetts Couple Leads Crusade Against Uterine Morcellation Following Wife's Cancer Diagnosis, Bernstein Liebhard LLP Report
NEW YORK, July 8, 2014 /PRNewswire/ -- As the Firm continues to investigate power morcellator lawsuits (http://www.gynecaremorcellatorlawsuit.com/), Bernstein Liebhard LLP wishes to acknowledge the work of the Massachusetts couple who have been leading the fight to ban uterine morcellation. In a video posted by The Cancer Letter on July 3rd, Dr. Hooman Noorchashm, a cardiothoracic surgeon, and his wife, Dr. Amy Reed, an anesthesiologist, poignantly discuss how Dr. Reed was diagnosed with leiomyosarcoma following a morcellation procedure she underwent last October to remove uterine fibroids. Despite having undergone an ultrasound and other screening prior to her laparoscopic hysterectomy, it was discovered just days after the surgery that Dr. Reed's uterus actually contained the rare but aggressive uterine cancer. Today, the 41-year-old mother of six is undergoing aggressive chemotherapy to treat stage 4 leiomyosarcoma.
"Since Dr. Reed's cancer diagnosis last year, she and her husband have led the fight to ban power morcellation. Without their efforts, it's doubtful that this issue would be receiving the attention it deserves," says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now offering free morcellator lawsuit reviews to women who may have experienced the spread of undiagnosed uterine sarcoma and other cancers due to uterine morcellation.
Power Morcellator Risks
Power morcellators are used in minimally-invasive uterine surgeries to shred tissue so that it can be removed from the body via a small abdominal incision. In the video posted by The Cancer Letter, Drs. Reed and Noorchashm relate how her surgeon reassured Dr. Reed that a laparoscopic hysterectomy was the best option for treating the fibroids that had plagued her for years. Among other things, the couple was not told that morcellation would be a part of the procedure, nor were they advised of the risks associated with these types of surgeries. When Dr. Noorchashm was told of his wife's diagnosis just a few days after the surgery, along with the revelation that a morcellator had been used to shred the tissue, his experience as a surgeon told him that Dr. Reed's cancer had certainly spread.
Since then, the Dr. Noorchashm has waged a national campaign to put an end to the practice of power morcellation. His efforts include a Change.org petition that as of July 8th had attracted more than 11,400 signatures. As a result of Dr. Noorchashm's work, Brigham & Women's Hospital – where Dr. Reed had her surgery - has suspended the use of power morcellators. Other hospitals around the country have also stopped or greatly limited such procedures.
Dr. Noorchashm's crusade will culminate on July 10th, when the U.S. Food & Drug Administration's (FDA) Obstetrics and Gynecological Devices Panel meets to discuss ways to mitigate the risks associated with power morcellation. Among the options the panel will consider over the two-day meeting is a total ban on uterine morcellation.
The FDA has already gone on record to discourage physicians from using the technique. On April 17th, the agency issued an alert asking that doctors reconsider the use of power morcellation in gynecological surgeries in light of their potential to spread uterine sarcomas and other cancers outside of the uterus. According to the agency, 1 in 350 women undergoing fibroid removal have uterine sarcoma cancer cells in their fibroids, and their chances of long-term survival are greatly reduced if the cancer cells are disseminated through morcellation.
Women who may have experienced the spread of uterine sarcomas or other cancers following uterine morcellation may be eligible to file a morcellator cancer lawsuit against the company that manufactured the device used in their surgery. To learn more about filing a morcellator lawsuit, please visit Bernstein Liebhard LLP's website. Free case reviews can also be obtained by calling (888) 340-4807.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorney fees unless their case results in a successful recovery on their behalf. New York State's contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm's fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff's recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(888) 340-4807
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Logo - http://photos.prnewswire.com/prnh/20120202/MM47134LOGO
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.gynecaremorcellatorlawsuit.com/
https://plus.google.com/115936073311125306742?rel=author
SOURCE Bernstein Liebhard LLP
Share this article